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http://dx.doi.org/10.1016/j.stemcr.2017.03.011SUMMARYReprogramming somatic cells to induced pluripotent stem cells (iPSCs) offers the possibility of studying the molecular mechanisms un-
derlying human diseases in cell types difficult to extract from living patients, such as neurons and cardiomyocytes. To date, studies have
been published that use small panels of iPSC-derived cell lines to study monogenic diseases. However, to study complex diseases, where
the genetic variation underlying the disorder is unknown, a sizable number of patient-specific iPSC lines and controls need to be gener-
ated. Currently the methods for deriving and characterizing iPSCs are time consuming, expensive, and, in some cases, descriptive but
not quantitative. Here we set out to develop a set of simple methods that reduce cost and increase throughput in the characterization
of iPSC lines. Specifically, we outline methods for high-throughput quantification of surface markers, gene expression analysis of
in vitro differentiation potential, and evaluation of karyotype with markedly reduced cost.INTRODUCTION
A crucial problem in both the analysis of many human
diseases and the development of effective therapies to treat
disease is the incomplete understanding of the role played
by human genetic variation in their development. An
important translational tool needed to solve this problem
is an in vitro cellular model derived from large numbers of
individualswhodisplayboth sporadic and inheriteddisease
as well as healthy controls. Pluripotent stem cells can pro-
vide disease-relevant cell types to model human diseases.
Todate,manycell typeshavebeenderived frompluripotent
cell lines, and exciting advances in disease modeling and
drug screening have been published (Avior et al., 2016;
Brennand et al., 2011; Israel et al., 2012; Itzhaki et al.,
2011; Mertens et al., 2015). However, a current limitation
to using induced pluripotent stem cells (iPSCs) to model
human disease is the time-inefficiency and cost of stan-
dard characterization methods required after reprogram-
ming. Furthermore, to model certain diseases, hundreds
of patient-specific pluripotent lines are necessary to be
adequately powered to test the relationship of genetic vari-
ants with cellular phenotypes and disease development.
Current methods for assessing pluripotency are low-
throughput and expensive. With the development of
several large biobanks of iPSCs to serve as resources for
studying human genetic variation and disease (Kilpinen
et al., 2016; McKernan and Watt, 2013; Panopoulos et al.,This is an open access arti2017 [this issue of Stem Cell Reports]; Salomonis et al.,
2016), the need to find low-cost, high-throughput solu-
tions to characterize iPSC pluripotency and genomic integ-
rity has become a high priority. The teratoma assay, which
measures human iPSC pluripotency in vivo, requires the
injection of iPSCs into immunodeficient mice. This assay
is expensive, technically challenging, time consuming,
and can be inconsistent in results (Andrews et al., 2015).
Embryoid body (EB) formation assays (Kurosawa, 2007)
provide a cheaper and less labor-intensive alternative by
testing the ability of iPSC lines to differentiate into the
three germ layers (mesoderm, endoderm, and ectoderm)
in vitro. This method is easily scalable because it does not
require addition of growth factors or plating of cells on
matrices to induce lineage differentiation, and can be
readily performed in a multiwell format. However, neither
the teratoma nor EB assays enable one to distinguish be-
tween high-quality iPSC lines composed of a high percent-
age of pluripotent stem cells from those that may be more
heterogeneous in nature but that contain a subpopulation
of cells that are pluripotent. Therefore, to maximize the
ability to utilize hundreds of iPSC lines for genetic studies,
researchers need methods to assess both pluripotency and
heterogeneity in an efficient manner.
Flow cytometry can assess cell-surface expression of
pluripotent markers (e.g., TRA-1-60, TRA-1-81) at the
single-cell level and is easily scalable using fluorescent cell
barcoding (FCB) (Krutzik and Nolan, 2006). In FCB, eachStem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017 j 1101
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sample in each well is labeled with a different signature, or
barcode, of fluorescent dyes with variable intensities and
emission wavelengths. Samples from multiple wells are
pooled together prior to staining with antibodies specific
for the markers of interest and then analyzed by flow cy-
tometry. This method reduces antibody consumption by
100-fold, eliminates staining variability between samples,
and decreases acquisition time per plate to 5–15 min (Krut-
zik and Nolan, 2006). Importantly, FCB enables one to
distinguish between high-quality iPSC lines composed of
predominantly pluripotent stem cells from those that are
heterogeneous. Conversely, while existing gene expres-
sion-based assays, such as PluriTest and TaqMan hPSC
Scorecard Assay (Muller et al., 2011; Tsankov et al., 2015),
cannot account for heterogeneous cell populations, they
can provide an accurate view of pluripotency and the dif-
ferentiation potential of iPSCs, respectively, based on the
expression of a larger number of genes. Therefore, the
optimal solution to determine heterogeneity and pluripo-
tency of iPSCs may be a combination of flow cytometry
and gene expression assays.
Genomic integrity is also essential to characterize, as
somatic copy-number variants (CNVs) could potentially
affect cellular function or, in the case of genetic studies,
the interpretation of inherited variants. At present, it is
standard practice to monitor genomic stability of iPSCs
by G-band karyotype analysis, which has allowed the
detection of large duplications involving genes that could
potentially affect pluripotency and differentiation poten-
tial (Maitra et al., 2005; Spits et al., 2008; Wu et al.,
2008). This technique is generally performed by trained
cytogeneticists in commercial laboratories, is costly, and
requires the preparation and shipment of live cells. The res-
olution of this technique is, at best, limited to a chromo-
somal rearrangement of 5 Mb or larger (Elliott et al.,
2010), and is impractical for high-throughput analysis of
iPSCs. We and others initiated the use of SNP microarray
technology for the routine karyotyping of iPSCs using
arrays such as the Illumina HumanCoreExome BeadChip
(International Stem Cell Initiative et al., 2011; Laurent
et al., 2011; Mayshar et al., 2010; Panopoulos et al., 2017;
Taapken et al., 2011). This method is relatively inexpensive
(up to 6-fold cheaper than G-band karyotype analysis), has
high sensitivity, and has up to 50-fold better resolution
(100 kb) than karyotyping (Hulten et al., 2003; Wapner
et al., 2012). Previous studies using SNP arrays for exam-
ining genomic integrity, however, have not fully investi-
gated their sensitivity for detecting somatic CNVs in
subpopulations of cells in an iPSC line. Therefore, it is
still unknown to what extent arrays can detect subclonal
chromosomal rearrangements in an iPSC population.
The analysis of available methods suggests that a combi-
nation of several assays, including flow cytometry to inves-1102 Stem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017tigate heterogeneity, gene expression analysis to examine
in vitro differentiation potential, and high-resolution kar-
yotyping to detect chromosomal aberrations, is necessary
for a complete characterization of iPSC lines. Here, we
describe a cost-effective, high-throughput suite of these
methods including flow cytometry using FCB, qPCR (based
on 12 primer pairs) for expression analysis, and SNP
arrays for digital karyotyping (Figure 1), which will facili-
tate the characterization of the large numbers of iPSC lines
currently being generated in individual laboratories as well
as in biobanks to examine human diseases.RESULTS
Reprogramming and Barcoding for Surface Marker
Expression
To develop a simple method for initial characterization of
reprogrammed cells by flow cytometry, we reprogrammed
fibroblasts from eight individuals using retroviruses with
a standard OCT4, KLF4, SOX2, and c-MYC cocktail
(OKSM). Additionally each factor had a GFP tag so that
silencing of retroviral factors could be monitored (Chan
et al., 2009). We included fibroblasts from two individuals
with a familial Alzheimer’s disease (FAD) mutation in the
amyloid b precursor protein (APP), twonon-demented con-
trol (NDC) individuals, three individuals with sporadic Alz-
heimer’s disease (SAD), and one individual with hippocam-
pal sclerosis (Table 1) to ensure that our methods would be
applicable for analysis of cell lines regardless of disease sta-
tus. All eight fibroblast lines generated colonies, and a total
of 294 individual colonies (range 24–50 colonies per fibro-
blast line) were manually picked based on morphology
(compact, circular) and absence of GFP, indicating that
retroviral factors had been silenced (Table 2). Individual
colonies were subsequently passaged and expanded for
additional characterization.
With traditional characterization methods, each iPSC
line was tested individually for expression of pluripotency
markers by immunofluorescence or flow cytometry. To
accelerate this process, reduce antibody consumption,
eliminate staining variability between samples, and
decrease the cost of measuring expression of pluripotent
markers, we adapted FCB (Krutzik and Nolan, 2006) for
use with iPSCs. As depicted in Figure 2, we optimized FCB
using three dyes (three concentrations of Alexa 750, four
concentrations of Alexa 647, and five concentrations of
Pacific Blue) to allow analysis of TRA-1-60 or TRA-1-81 in
60 different iPSC lines simultaneously.
To test whether the FCB technique would be able
to distinguish between high- and low-quality iPSCs, we
performed a pilot experiment with a human embryonic
stem cell (hESC) line (HUES9), a high-quality iPSC line
Figure 1. Workflow to Characterize iPSC
Lines
Simple and cost-effective methods for
determining heterogeneity, differentiation
potential, and genome integrity of iPSC
lines. Heterogeneity is assessed by flow
cytometry on up to 60 iPSC lines simulta-
neously using barcoding optimization.
In vitro differentiation potential is exam-
ined by qPCR using 12 marker genes on up to
96 samples. Digital karyotype is determined
using Illumina genotyping BeadChips.(NDC1), and a low-quality iPSC line (CV-hiPS-F). The high-
quality iPSC line was previously generated in our labora-
tory (Israel et al., 2012) and displays high expression of
pluripotent markers and the ability to differentiate into
the three germ layers. The low-quality iPSC line was also
generated in our laboratory (Gore et al., 2011) and was
characterized as such due to the presence of GFP-positive
(GFP+) cells (indicating retroviral reactivation), low expres-
sion of pluripotent markers, irregular colony morphology,
and an abnormal karyotype. Three biological replicates of
each cell line were barcoded (Figure 3A), divided into two
tubes (with one tube stained with TRA-1-60 and the other
stained with TRA-1-81), and analyzed for the presence of
GFP+ cells (Figures 3 and S1). The hESC line and the high-
quality iPSC line exhibited no GFP+ cells (Figures 3B and
3D), while the low-quality iPSC line displayed GFP+ cells
(Figure 3F). In addition, the hESC line and high-quality
iPSC line exhibited a higher number of cells positive for
TRA-1-81 (>97%) than the low-quality iPSC line (87.4%,
p = 0.025, Wilcoxon rank-sum test) (Figures 3C, 3E, 3G,
and S1). Based on the results from our pilot experiment,
it is clear that using FCB to examine the percentage of cells
expressing pluripotent markers can distinguish between
high- and low-quality iPSCs.
To test whether FCB could support analysis of large
numbers of lines, we analyzed iPSC lines from our reprog-ramming collection by FCB for expression of TRA-1-60
and TRA-1-81, and absence of GFP at passage 3 (P3). From
the 294 colonies that were manually picked (Table 2), 162
(55%) maintained good colony morphology (compact,
circular) during expansion and were analyzed by FCB. Of
these 162 iPSC lines, 149 (92%) lines were high-quality
lines (i.e., had high expression levels of TRA-1-60 and
TRA-1-81 and no GFP+ cells, as depicted in Figure 3)
(Table 2), and were subsequently frozen down for further
analysis. Thus, FCB is a highly scalable assay that can effi-
ciently characterize hundreds of iPSC lines.
Twelve-Gene qPCR to Assess In Vitro Differentiation
Potential
We sought to establish a quantitative method that was
both easy to implement and had a straightforward analysis
approach to test whether reprogrammed cells had pluripo-
tent gene expression and an ability to differentiate in vitro.
Of the 149 iPSC lines expressing cell-surface pluripotency
markers, we chose 58 to test by qPCR for gene expression
signatures of pluripotency and the ability to differentiate
into the three germ layers (mesoderm, endoderm, and
ectoderm). We conducted undirected EB differentiation of
these 58 iPSC lines (Table S1) and interrogated 30 markers
of pluripotency and markers for each of the three germ
layers (9 ectoderm, 8 endoderm, and 17 mesoderm) byStem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017 1103
Table 1. Summary of Fibroblast and Subject Information
Fibroblast Name Family History Diagnosis Age at Biopsy Age of Onset MMSEa APOEb Sex
APPc V717F-1 yes FADd unknown unknown unknown 3/3 M
APPc V717F-2 yes FAD unknown unknown unknown 3/3 F
NDC4 no NDCe 84 NA 30 3/3 M
NDC5 no NDC 79 NA 30 3/3 M
SAD3f,g yes PADh 89 82 23 3/3 M
SAD4 yes PAD 79 74 24 3/3 F
SAD5 yes PAD 84 80 26 3/3 F
SAD6 yes PAD 81 78 24 3/3 M
aMMSE, Mini Mental State Examination (Folstein et al., 1975).
bApolipoprotein E (APOE) genotype indicates carriers are homozygous for the ε3 allele.
cAPP, amyloid precursor protein.
dFAD, familial Alzheimer’s disease.
eNDC, non-demented control.
fSAD, sporadic Alzheimer’s disease.
gUpon autopsy, individual SAD3 was reported to have hippocampal sclerosis, not SAD.
hPAD, probably Alzheimer’s disease.qPCR, normalizing the expression data using the house-
keeping gene RPS29 (see Experimental Procedures) (Tables
S2 and S3). While conducting a quality check of the
qPCR results (measured as ‘‘Ct’’), six iPSC-EB pairs were
removed because one or both samples were found to be
of insufficient quality based on the following criteria: (1)
RPS29, the housekeeping gene used for normalization,
was not expressed; (2) less than 50% of the tested genes
were expressed; or (3) more than 50% of the tested genes
were aberrantly expressed (defined as an expression level
greater than two SDs from its mean expression value
across all samples after normalization to RPS29). Using a
principal component analysis (PCA) on the expression pro-
files of these 64 marker genes, we analyzed 110 samples
comprising 52 iPSCs, 52 associated EBs, and six ESCs
included as controls (Figures 4A–4E), and confirmed that
the expression levels of these genes were able to distinguish
between pluripotent and differentiated cell lines.
To make the qPCR method as cost-effective and stream-
lined as possible, we next analyzed the 64 marker genes
to choose an optimal set of 12 markers that would be suffi-
cient to establish the differentiation potential of iPSCs. To
achieve this, we took advantage of the fact that iPSCs were
found to be associated with low values of principal compo-
nent 2 (PC2) and PC3, whereas EBs had low values of PC2
and PC3 (Figures 4A–4C). We chose four genes per germ
layer with the most negative weights on PC2 (Figure 4D).
We then determined how well these 12 markers were able
to detect the presence of the three germ layers in the
derived EBs. Expression levels for the 12 genes were1104 Stem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017normalized across all 110 samples (minimum = 0 and
maximum = 1). For each germ layer, we defined a ‘‘germ
layer score’’ as the mean normalized expression values of
the four genes most associated with each germ layer. We
found that the ESCs and iPSCs have very low germ layer
scores, while the majority of the EBs have high scores for
all three germ layers (Figure 4E). As expected (Tsankov
et al., 2015), the relative strength of the three germ layer
scores varied across the EBs, suggesting that they had
different proportions of ectoderm, endoderm, and meso-
derm cells. These data suggest that the in vitro differentia-
tion potential of iPSC can be efficiently examined by assay-
ing derived EBs for expression of these 12 genes. To make
pluripotency and multilineage differentiation analysis
accessible, we include a supplementary file, Data S1, a
Microsoft Excel table that allows users to generate pluripo-
tency and/or germ layer scores and corresponding heat-
maps using Ct values of a housekeeping gene and marker
genes of interest.
Digital Karyotyping for Detecting Chromosome
Alterations
To establish a method for calling digital karyotypes using
the Illumina HumanCoreExome BeadChip, we first calcu-
lated the percentage of cells within a population that were
required to detect a chromosome alteration. We used the
low-quality iPSC sample, CV-hiPS-F (Gore et al., 2011),
which was reported by standard G-banding to have tri-
somy 12, 13, 14, 17, 20, and XXY. The reported frequency
of these abnormalities was 90% (18 of 20 cells analyzed
Table 2. Summary of Reprogramming Results
Fibroblast






No. of Lines that Grew
to P3 for Barcoding
No. of Lines Frozen (TRA-1-60+
and TRA-1-81+ with No GFP
APP V717F-1 96.3 >100 49 27 24
APP V717F-2 95.0 >100 32 14 14
NDC4 85.0 36 36 15 14
NDC5 88.3 25 25 20 17
SAD3 76.4 24 24 20 20
SAD4 93.0 >100 44 24 23
SAD5 92.4 >100 34 30 28
SAD6 94.6 >100 50 12 9by karyotype analysis at WiCell). Using a genetically
matched clone of CV-hiPS-F that has a normal karyotype
(CV-hiPS-B), we performed a serial dilution of the DNA
from CV-hiPS-F (100%, 50%, 25%, 12.5%, 6.25%, 0%)
and hybridized the six samples to the HumanCoreExome
BeadChip (Figure 5A). These arrays produce data from in-
tensity signals corresponding to the presence of allele A
and allele B at a given SNP. Using GenomeStudio (Illu-
mina), we calculated the mean log R ratio (LRR, Tables
S4 and S5), a measure of copy number as a ratio of
observed to expected intensities; and the B-allele fre-
quency (BAF, Table S6), the proportion of allele calls
at each genotype with respect to allele B (1.0 for B/B,
0.5 for A/B, and 0.0 for A/A). We created plots using
these metrics to visually inspect each chromosome for
abnormalities, and present the findings for chromosomes
13 and 14 in Figure 5A. The BAF and LRR plots depict
the disappearance of the trisomic signal of chromosomes
13 and 14 between the 25% and 12.5% dilution samples,
indicating that the array is sensitive enough to detect
abnormal cells present at about 20% frequency (undiluted
DNA has 90% abnormal cells).
To further examine the percentage of abnormal cells
detectable by the array, we calculated the mean BAF dis-
tance between abnormal (ABB/AAB) and normal (AB) ge-
notypes on the array by filtering the data for the heterozy-
gous SNPs coming from the abnormal autosomes (12, 13,
14, 17, and 20). The signal intensities of the six dilution se-
ries datasets were each divided into two clusters based on
whether they were above or below the median BAF value.
The ‘‘AAB’’ cluster included all SNPs with BAF greater than
the median BAF, while the ‘‘ABB’’ cluster had BAF values
less than the median BAF. The mean BAF value was then
calculated for the ABB and AAB groups; the difference be-
tween these values yielded the BAF mean distance. A high
BAF mean distance signifies a clear signature for a trisomy,
whereas a lower value signifies normal diploid DNA. Thesedistances were then plotted (Figure 5B), providing addi-
tional evidence that the array can detect abnormal cells
that are present at a 20% or greater frequency (between
the 25% and 12.5% dilution samples). This observed
detection sensitivity shows that SNP arrays can detect
possibly harmful alterations in small subpopulations of
iPSC lines.DISCUSSION
Here we provide a workflow that enables rapid and cost-
effective characterization of iPSC lines. Our suite of
methods combines FCB, 12-gene qPCR, and SNP arrays to
measure heterogeneity, expression levels of differentiation
genes, and chromosomal aberrations, respectively. The
FCB method can substantially reduce the labor and time
required for performing flow cytometry as up to 60 iPSC
samples can be processed simultaneously (Figure 1).
Because FCB is conducted in a 96-well format, it can
significantly reduce antibody consumption and eliminate
staining variability between samples. The high-throughput
nature of FCB and the fact that the only instrument
required is a flow cytometer, which is present in most
research facilities, allows it to be readily incorporated into
workflows for characterizing the pluripotency of large-scale
iPSC collections on a per-line cost basis of $12 (based on
cost of $1,200 to purchase all dyes for barcoding, and
TRA-1-60 and TRA-1-81 antibodies, which can be used to
label 100 samples).
The qPCR method we describe uses the expression levels
of only 12 genes to provide a qualitative assessment of each
of the three germ layers (four genes each), which is a cost-
effective and high-throughput approach to rapidly assess
the pluripotency and basic differentiation potential of
iPSCs. Although we used a Fluidgm Biomark HD instru-
ment (full Biomark chip costs$1,500 to runwith reagentsStem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017 1105
Figure 2. Optimization of Fluorescent Cell Barcoding Technique for Use with iPSCs
(A) FCB setup for barcoding 60 iPSC samples using three dyes: Alexa 750, Alexa 647, and Pacific Blue. FCB was optimized to include three
concentrations of Alexa 750 (0, 5, 15 mg/mL), four concentrations of Alexa 647 (0, 0.6, 3, 15 mg/mL), and five concentrations of Pacific
Blue (0, 0.4, 1.6, 6.4, 25 mg/mL).
(B) Efficient barcoding of iPSCs with Alexa 647 and Pacific Blue allows clear distinction of 20 iPSC populations stained with different
concentrations of these two dyes.
(C–E) The three populations indicated in (B) are each deconvoluted into three distinct iPSC lines based on staining with Alexa 750. SSC,
side-scattered light.and labor) to develop our approach, standard qPCR instru-
ments that are present inmost research facilities can be uti-
lized to run the 12-gene qPCR on a per-line cost basis of
$20 (based on a cost of$100 to purchase IDT PrimeTime
qPCR Assay and $70 for Probe-Based qPCR Master Mix
which can be used for 100 samples). This enables the simul-
taneous interrogation of hundreds of samples for the
expression ofmarkers for each of the three germ layers (Fig-
ure 1) at substantially less cost than for available tests (such
as the commercially available ScoreCard) (Tsankov et al.,
2015). In Data S1, we provide an Excel spreadsheet that
allows the calculation of pluripotency and germ layer
scores for those interested in implementing our 12-gene
qPCR approach.
Using digital karyotyping by SNP arrays, the genomic
integrity of iPSC lines can be initially examined and also
easily monitored at different passages over time, which is
recommended due to genomic changes that can occur as
cells remain in culture, but in practice is not done with
conventional karyotyping due to costs. Importantly, we
showed that SNP arrays can be used to detect both clonal
(present in all iPSC cells) and subclonal (present in 20%1106 Stem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017or more cells) CNVs, suggesting that digital karyotyping
is a useful method to detect potentially harmful genomic
alterations that are present only in a subpopulation of
iPSCs within a line. While a full SNP array (24 individual
samples) (Figure 1) can cost $1,800 with reagent and labor
costs, on a per-line cost basis it is $75 ($1,800/24). Thus,
research facilities with Illumina microarray scanners can
readily implement digital karyotyping. (For researchers
without access to Illumina machines, samples may be
sent to our facility at University of California at San Diego
[UCSD]; see Experimental Procedures). In summary, our
suite of methods provides excellent characterization of
the heterogeneity, pluripotency, and genomic integrity of
an iPSC line for $110.EXPERIMENTAL PROCEDURES
iPSC Generation
iPSCs were generated as previously described (Israel et al., 2012)
with a few minor modifications. Each transcription factor vector
contained a GFP tag to allow for monitoring of silencing of retro-
viral factors (Chan et al., 2009). iPSCs were maintained on an
Figure 3. Fluorescent Cell Barcoding Can Distinguish between High- and Low-Quality iPSCs
(A) One hESC line (HUES9), one high-quality iPSC line (NDC1), and one low-quality iPSC line (CV-hiPS-F) were barcoded, stained with TRA-
1-81 and TRA-1-60 separately, and subsequently analyzed for GFP expression in three replicates (depicted as R1, R2, R3). Only data for
staining with TRA-1-81 are shown.
(B and C) The HUES9-R3 hESC (B) displays no GFP+ cells and (C) has 97.7% of cells TRA-1-81+.
(D and E) The NDC1-R1 high-quality iPSC line (D) displays no GFP+ cells and (E) has 96.9% of cells TRA-1-81+.
(F and G) The CV-hiPS-F-R2 low-quality iPSC line has (F) GFP+ cells, indicating retrovirus reactivation and (G) a lower fraction of TRA-1-81+
cells (86.3%).
FSC-W, forward-scattered light width. See also Figure S1.irradiated murine embryonic fibroblast (MEF) feeder layer with
medium containing knockout (KO) DMEM (Gibco), 20% KO
Serum Replacement (Gibco), 20 mM GlutaMax (Invitrogen),
20 mM non-essential amino acids (Invitrogen), 20 mM peni-
cillin-streptomycin (Invitrogen), and 20 ng/mL fibroblast growth
factor (FGF) (Millipore). Cells were passaged by dissociation with
Accutase (Innovative Cell Technologies).Fluorescent Cell Barcoding
FCB was performed as previously described (Krutzik and Nolan,
2006). In brief, in a 96-well format cells were fixed for 10 min at
room temperature in 4% paraformaldehyde. Following fixation,
cells were resuspended in 100% methanol with fluorescent dyes
(Life Technologies) and incubated at room temperature for
20 min. Cells were subsequently washed twice in PBS containingStem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017 1107
Figure 4. Germ Layer Scores Show Expression Differences between iPSCs and EBs
(A–C) Principal component analysis of expression of 64 marker genes as measured by qPCR using the Fluidigm Biomark platform: (A)
scatterplot PC1-PC2; (B) scatterplot PC1-PC3; (C) scatterplot PC2-PC3. The three plots show that the expression values of the 64 marker
genes are able to distinguish iPSCs from embryoid bodies (EBs).
(D) Scatterplot of theweights of each gene onPC2 (x axis) andPC3 (y axis). The 12genes selected for the qPCR are shown (and are also listed in
Table S2). Four genes for each germ layer were chosen because they contributed to the largest expression differences between iPSCs and EBs.
(E) Germ layer scores for iPSCs and EBs (top) and ESCs (bottom) were calculated as the mean value across the four genes in each set. The
majority of EBs display high scores for all three germ layers, whereas iPSCs and ESCs have low scores.
See also Tables S1–S3 and Data S1.
1108 Stem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017
Figure 5. Serial Dilution of an Abnormal iPSC Line to Establish
Detection Sensitivity
(A) Mean log R ratio (LRR, in red) and B-allele frequency (BAF, in
blue) in the six dilution states (0%, 6.25%, 12.5%, 25%, 50%, and
100%). Notably, the AAB/ABB trisomy specific BAF signal (the two
blue horizontal bands) transitions to the diploid AB BAF signal
(single blue band) as the amount of abnormal cell line in the assay
decreases. The black arrows highlight the heterozygous SNP band as
it changes from the AAB and ABB genotype (two blue bands) to the
AB genotype (one blue band). The disappearance of the double-
band AAB/ABB genotype to the single-band AB genotype indicates
the failure of the assay to detect the difference between abnormal
trisomic and normal diploid DNA, and thus we estimate the sensi-
tivity of the array to be between 12.5% and 25%.
(B) Plot displaying the mean BAF distance for chromosomes 12, 13,
14, 17, and 20 across the six dilution states. High BAF mean dis-
tance indicates a trisomic state, while a lower value signifies
normal diploid DNA.
See also Tables S4–S6.0.1% BSA. Barcoded cells where then combined together and
divided into two tubes: one tube of cells was stained with TRA-1-
60 and the other was stained with TRA-1-81 (BD Biosciences,
1:1,000). Barcoded samples were thenmeasured by flow cytometry
(BD Biosciences) and all data was analyzed using FlowJo Cell Anal-
ysis software. Only cells expressing high levels of bothmarkers and
that were GFP negative were used in qPCR analysis.
Embryoid Body Generation
EBs were generated as previously described (Bock et al., 2011). In
brief, iPSCs were lifted off the MEFs using dispase and were then
plated in low-attachment plates in the presence of IPSC culture
mediumwithout FGF. EBs were grown for 2 weeks and themedium
was changed every 48 hr.
qPCR Analysis
Primers were designed for 68 genes (4 housekeeping genes and 64
pluripotency or germ layer markers) using an in-house algorithm
that targeted: (1) a melting temperature of 60C; (2) regions that
spanned multiple exons when possible to minimize genomic
DNA signal contamination; and (3) exons that are shared between
multiple isoforms. In addition, the primerswere tested and showed
a single dominant melting curve peak consistent with a dominant
amplification product (see Table S2 for a list of primers).
To select the most consistently expressed housekeeping gene
for normalization, we tested four housekeeping genes (RPS29,
GAPDH, RPL22, and DSG2). We selected RPS29 because this gene
had the least variable Ct distribution across all samples (SD =
0.827), whereas the other three housekeeping genes had higher
variability (SD = 1.629, 1.623, and 1.642, respectively). The exclu-
sion of these three housekeeping genes resulted in the expression
of 65 genes being utilized (1 housekeeping and 64 marker genes).
RNA was isolated from samples using either TRIzol, Qiagen
RNeasy Mini Kit, or Qiagen AllPrep DNA/RNA kit. cDNA was
produced using Superscript III from 100–500 ng input RNA
using oligo(dT)20. Samples were prepared following the Fluidigm
Advanced Development Protocol v37, and qPCR was performedStem Cell Reports j Vol. 8 j 1101–1111 j April 11, 2017 1109
on the Fluidigm BioMark HD using EvaGreen and the GE96x96
Fast PCR protocol.Marker Gene Selection for 12-Gene qPCR
Gene expression (Ct) was normalized to RPS29 and used as input
for PCA. PCA was performed using the prcomp function in R and
PCs were visually inspected (Figure 4), with PC2 and PC3 found
to have the largest differences between iPSCs and EBs. EBs were
found to be associated with high values of PC2 and PC3, whereas
iPSCs had low values of PC2 and PC3. To calculate a ‘‘germ layer
score,’’ four genes per germ layer were chosen to be included
because they had the most negative weights on PC2 and PC3.
Expression levels for all genes were normalized across all 110 sam-
ples in order to have minimum = 0 and maximum = 1, and the
germ layer scores were calculated as the mean value across each
group of four genes. We include a supplementary file, Data S1, a
Microsoft Excel table that allows users to generate germ layer scores
using Ct values as input. Similarly, the user can use Data S1 to
generate pluripotency scores using Ct values for four pluripotency
markers (chosen by the user) as input.HumanCoreExome BeadChips
Using the services of the UCSD IGMGenomics Center (http://igm.
ucsd.edu/genomics/), genomic DNA from a normal iPSC line (CV-
hiPS-B) and a genetically identical abnormal iPSC line (CV-hiPS-F)
were extracted (AllPrep DNA/RNA Mini Kit, Qiagen), normalized
to 200 ng, serially diluted, hybridized to HumanCoreExome v12
arrays (Illumina), and stained and scanned using the Illumina HiS-
can system per standard protocol. We observed an average call rate
of 99.2% across the arrays.
The Institutional Review Board of the University of California at
San Diego approved the study and the subject whose DNA was
used for the HumanCoreExome BeadChips gave informed consent
(Project #071641).ACCESSION NUMBERS
The accession number for the HumanCoreExome BeadChip data
reported in this paper is ArrayExpress: E-MTAB-5587.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, one figure, six tables, and one data file and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2017.03.011.
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